AFYX THERAPEUTICS A/S – Trademark Portfolio
Entity Type: 65
AFYX THERAPEUTICS A/S holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include GEFENA, RIVELIN, and AFYX THERAPEUTICS. The owner is based in KØBENHAVN S.
LERGRAVSVEJ 57, 2. TV
KØBENHAVN S 2300 , DK
Showing of trademarks Trademarks
Trademark Classifications
AFYX THERAPEUTICS A/S's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does AFYX THERAPEUTICS A/S have?
AFYX THERAPEUTICS A/S has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.
What trademark classes does AFYX THERAPEUTICS A/S file in?
AFYX THERAPEUTICS A/S files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are AFYX THERAPEUTICS A/S's most well-known trademarks?
AFYX THERAPEUTICS A/S's registered trademark portfolio includes well-known marks such as GEFENA, RIVELIN, and AFYX THERAPEUTICS. These are among 3 currently registered trademarks in the portfolio.
What is AFYX THERAPEUTICS A/S's trademark registration success rate?
AFYX THERAPEUTICS A/S has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.